Institute for Health, Health Care Policy, and Aging Research (Walkup, Hermida, Crystal) and Graduate School of Applied and Professional Psychology (Walkup), Rutgers University, New Brunswick, New Jersey; Department of Epidemiology and Biostatistics (Thomas, Vittinghoff, Mangurian), Department of Psychiatry and Behavioral Sciences (Thomas, Dahiya, Dilley, Bazazi, Mangurian), and Center for AIDS Prevention Studies (Arnold), University of California San Francisco School of Medicine, San Francisco; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York City (Olfson, Cournos); New York State Psychiatric Institute, New York City (Olfson); Kaiser Family Foundation, Washington, D.C. (Dawson).
Psychiatr Serv. 2023 Jul 1;74(7):709-717. doi: 10.1176/appi.ps.20220311. Epub 2023 Feb 28.
People with schizophrenia have more HIV risk factors and higher rates of HIV infection than the general U.S. population. The authors aimed to examine HIV testing patterns in this population nationally and by demographic characteristics and presence of high-risk comorbid conditions.
This retrospective longitudinal study compared HIV testing between Medicaid-only enrollees with schizophrenia and without schizophrenia during 2002-2012 (N=6,849,351). Interrupted time series were used to analyze the impacts of the 2006 federal policy change recommending expanded HIV testing. Among enrollees with schizophrenia, multivariable logistic regression was used to estimate associations between testing and both demographic characteristics and comorbid conditions. Sensitivity analyses were also conducted.
Enrollees diagnosed as having schizophrenia had consistently higher HIV testing rates than those without schizophrenia. When those with comorbid substance use disorders or sexually transmitted infections were excluded, testing was higher for individuals without schizophrenia (p<0.001). The federal policy change likely increased testing for both groups (p<0.001), but the net change was greater for those without schizophrenia (3.1 vs. 2.2 percentage points). Among enrollees with schizophrenia, testing rates doubled during 2002-2012 (3.9% to 7.2%), varied across states (range 17 percentage points), and tripled for those with at least one annual nonpsychiatric medical visit (vs. no visit; adjusted OR=3.10, 95% CI=2.99-3.22).
Nationally, <10% of enrollees with schizophrenia had annual HIV testing. Increases appear to be driven by high-risk comorbid conditions and nonpsychiatric encounters, rather than by efforts to target people with schizophrenia. Psychiatric guidelines for schizophrenia care should consider HIV testing alongside annual metabolic screening.
精神分裂症患者比美国一般人群具有更多的艾滋病毒风险因素和更高的艾滋病毒感染率。作者旨在全国范围内以及按人口统计学特征和高危合并症的存在情况来检查该人群中的艾滋病毒检测模式。
本回顾性纵向研究比较了 2002 年至 2012 年间仅参加医疗补助计划的精神分裂症患者和未患精神分裂症患者的艾滋病毒检测情况(N=6849351)。采用中断时间序列分析来分析 2006 年联邦政策改变建议扩大艾滋病毒检测的影响。对于患有精神分裂症的患者,采用多变量逻辑回归来评估检测与人口统计学特征和合并症之间的关系。还进行了敏感性分析。
诊断为患有精神分裂症的患者的艾滋病毒检测率始终高于未患精神分裂症的患者。当排除同时患有物质使用障碍或性传播感染的患者后,未患精神分裂症的患者的检测率更高(p<0.001)。联邦政策的改变可能增加了两组的检测(p<0.001),但未患精神分裂症的患者的净变化更大(3.1 个百分点对 2.2 个百分点)。在患有精神分裂症的患者中,2002 年至 2012 年期间检测率翻了一番(从 3.9%增加到 7.2%),各州之间存在差异(范围为 17 个百分点),每年至少有一次非精神科就诊的患者的检测率增加了两倍(与无就诊相比;调整后的 OR=3.10,95%CI=2.99-3.22)。
全国范围内,不到 10%的精神分裂症患者每年接受艾滋病毒检测。检测率的增加似乎是由高危合并症和非精神科就诊驱动的,而不是针对精神分裂症患者的努力。精神分裂症护理的精神病学指南应考虑将艾滋病毒检测与年度代谢筛查相结合。